Market Overview:
The global amifampridine market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The patent protected amifampridine segment is expected to hold a larger share in the global market, while the generic amifampridine segment is projected to grow at a higher CAGR during the forecast period. The myasthenia gravis application segment is estimated to account for a larger share of the global market in 2018, while potassium channel blocker application segment is projected to grow at a higher CAGR during the forecast period. North America dominates the global market for amifampridine due to well-established healthcare infrastructure and increasing prevalence of neuromuscular disorders such as myasthenia gravis and ALS. However, Asia Pacific region offers lucrative growth opportunities for players operating in this market due high population base and increasing awareness about available treatment options for neuromuscular disorders.
Product Definition:
Amifampridine (4-aminopyridine) is a medication used to improve walking in people with multiple sclerosis. It is a potassium channel blocker.
Generic:
Amifampridine is a generic medicine, which is used for the treatment of malaria. It's an off-label drug, approved by the Food and Drug Administration (FDA) for treatment of malaria caused by Plasmodium vivax and Plasmodium falciparum. The drug was first sold in Europe as Jervanor among others; however, it received FDA approval only in 2015.
Patent:
Patent is a legal right granted to an individual or a company for inventions related to new drug molecules, manufacturing processes, and new medical devices. In order to obtain patent the product or process should be novel and useful. Novel means not previously known to the public. The product must not be generic in nature as that would mean it is easily available on account of no longer being novel. It must also be different from any products which are already patented by other companies.
Application Insights:
Based on the application, the global market is segmented into myasthenia gravis, potassium channel blocker and others. The potassium channel blocker segment dominated the overall industry in terms of revenue in 2017. Amifampridine is used for treating myasthenia gravis as well as other movement disorders such as Parkinson¢â‚¬â„¢s disease and essential tremors. However, there are no generic alternatives available for amifampridine due to its proprietary nature; hence this factor limits its usage in potassium channel blockage therapy across the globe.
The other applications include post-myocardial infarction treatment of patients with chronic heart failure and pre-operative preparation for patients undergoing spinal surgery or trauma care unit admission.
Regional Analysis:
North America dominated the global market in 2017. The region is expected to maintain its position throughout the forecast period owing to increasing cases of myasthenia gravis and favorable reimbursement policies for commercial products. In addition, rising awareness about AMPA receptoropathies and their treatment options is anticipated to propel product demand in North America over the forecast period.
Asia Pacific is expected to witness lucrative growth over the coming years due to rapidly improving healthcare infrastructure, economic development, and increased focus of major pharmaceutical companies on this region. China accounted for a revenue share of 23% in Asia Pacific market in 2017 owing to high unmet clinical needs coupled with low cost structure associated with local production of amifampridine tablets & capsules (5 mg/0.5 mg). This trend is anticipatedto continue overthe next eight years as reported by Merck KGaA’s Chinese subsidiary Qilu Pharmaceutical Group Co., Ltd.
Growth Factors:
- Increasing prevalence of neuromuscular diseases: The global prevalence of neuromuscular diseases is increasing due to the aging population and the increased incidence of autoimmune disorders. This is expected to drive the demand for amifampridine, as it is one of the few approved treatments for these conditions.
- Growing awareness about amifampridine: There is growing awareness about the benefits of amifampridine among patients and healthcare professionals, which is likely to drive its adoption in the coming years.
- Availability of generic versions: The availability of generic versions of amifampridine has made it more affordable and accessible, thus driving its uptake in countries where it is available.
- Emerging markets offer potential growth opportunities: The emerging markets offer significant potential growth opportunities for the Amifampridine market due to their large population base and increasing incidence rates of neuromuscular diseases.
Scope Of The Report
Report Attributes
Report Details
Report Title
Amifampridine Market Research Report
By Type
Generic, Patent
By Application
Myasthenia Gravis, Potassium Channel Blocker
By Companies
Jacobus Pharmaceutical, Unichem, BioMarin Pharmaceutical, Wockhardt, Glenmark Pharmaceuticals, Norris Pharm, BLD Pharm, Biosynth AG, Innovapharm, Founder Pharma, BroadPharm, CSNpharm, Merck
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
121
Number of Tables & Figures
85
Customization Available
Yes, the report can be customized as per your need.
Global Amifampridine Market Report Segments:
The global Amifampridine market is segmented on the basis of:
Types
Generic, Patent
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Myasthenia Gravis, Potassium Channel Blocker
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Jacobus Pharmaceutical
- Unichem
- BioMarin Pharmaceutical
- Wockhardt
- Glenmark Pharmaceuticals
- Norris Pharm
- BLD Pharm
- Biosynth AG
- Innovapharm
- Founder Pharma
- BroadPharm
- CSNpharm
- Merck
Highlights of The Amifampridine Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Generic
- Patent
- By Application:
- Myasthenia Gravis
- Potassium Channel Blocker
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Amifampridine Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Amifampridine is a medication used to treat certain types of seizures. It is also used to prevent and treat malaria.
Some of the major players in the amifampridine market are Jacobus Pharmaceutical, Unichem, BioMarin Pharmaceutical, Wockhardt, Glenmark Pharmaceuticals, Norris Pharm, BLD Pharm, Biosynth AG, Innovapharm, Founder Pharma, BroadPharm, CSNpharm, Merck.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Amifampridine Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Amifampridine Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Amifampridine Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Amifampridine Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Amifampridine Market Size & Forecast, 2018-2028
4.5.1 Amifampridine Market Size and Y-o-Y Growth
4.5.2 Amifampridine Market Absolute $ Opportunity
Chapter 5 Global Amifampridine Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Amifampridine Market Size Forecast by Type
5.2.1 Generic
5.2.2 Patent
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Amifampridine Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Amifampridine Market Size Forecast by Applications
6.2.1 Myasthenia Gravis
6.2.2 Potassium Channel Blocker
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Amifampridine Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Amifampridine Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Amifampridine Analysis and Forecast
9.1 Introduction
9.2 North America Amifampridine Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Amifampridine Market Size Forecast by Type
9.6.1 Generic
9.6.2 Patent
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Amifampridine Market Size Forecast by Applications
9.10.1 Myasthenia Gravis
9.10.2 Potassium Channel Blocker
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Amifampridine Analysis and Forecast
10.1 Introduction
10.2 Europe Amifampridine Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Amifampridine Market Size Forecast by Type
10.6.1 Generic
10.6.2 Patent
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Amifampridine Market Size Forecast by Applications
10.10.1 Myasthenia Gravis
10.10.2 Potassium Channel Blocker
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Amifampridine Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Amifampridine Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Amifampridine Market Size Forecast by Type
11.6.1 Generic
11.6.2 Patent
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Amifampridine Market Size Forecast by Applications
11.10.1 Myasthenia Gravis
11.10.2 Potassium Channel Blocker
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Amifampridine Analysis and Forecast
12.1 Introduction
12.2 Latin America Amifampridine Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Amifampridine Market Size Forecast by Type
12.6.1 Generic
12.6.2 Patent
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Amifampridine Market Size Forecast by Applications
12.10.1 Myasthenia Gravis
12.10.2 Potassium Channel Blocker
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Amifampridine Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Amifampridine Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Amifampridine Market Size Forecast by Type
13.6.1 Generic
13.6.2 Patent
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Amifampridine Market Size Forecast by Applications
13.10.1 Myasthenia Gravis
13.10.2 Potassium Channel Blocker
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Amifampridine Market: Competitive Dashboard
14.2 Global Amifampridine Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Jacobus Pharmaceutical
14.3.2 Unichem
14.3.3 BioMarin Pharmaceutical
14.3.4 Wockhardt
14.3.5 Glenmark Pharmaceuticals
14.3.6 Norris Pharm
14.3.7 BLD Pharm
14.3.8 Biosynth AG
14.3.9 Innovapharm
14.3.10 Founder Pharma
14.3.11 BroadPharm
14.3.12 CSNpharm
14.3.13 Merck
